• 1
    Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.Ann Rheum Dis2010;69:96475.
  • 2
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al.Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent.N Engl J Med2001;345:1098104.
  • 3
    Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al.Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.Ann Rheum Dis2010;69:97686.
  • 4
    Gomez-Reino JJ, Carmona L, Angel Descalzo M, for the Biobadaser Group.Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.Arthritis Rheum2007;57:75661.
  • 5
    Nolan CM, Goldberg SV, Buskin SE.Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.JAMA1999;281:10148.
  • 6
    British Thoracic Society Standards of Care Committee.British Thoracic Society recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment.Thorax2005;60:8005.
  • 7
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis Rheum2008;59:76284.
  • 8
    Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al.Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.J Rheumatol2012;39:1583602.
  • 9
    American Thoracic Society.Targeted tuberculin testing and treatment of latent tuberculosis infection.Am J Respir Crit Care Med2000;161:S22147.
  • 10
    Public Health Agency of Canada. Canadian tuberculosis standards. 6th ed.2007. URL:
  • 11
    Horsburgh CR Jr.Priorities for the treatment of latent tuberculosis infection in the United States.N Engl J Med2004;350:20607.
  • 12
    Menzies D. The online TST/IGRA interpreter, version 3.0.2009. URL:
  • 13
    Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M.Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results.Int J Tuberc Lung Dis2008;12:498505.
  • 14
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al.Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.Arthritis Rheum2005;52:198692.
  • 15
    Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S.Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.Arthritis Rheum2009;61:3004.
  • 16
    Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al.Increased risk of tuberculosis in patients with rheumatoid arthritis.J Rheumatol2003;30:14369.
  • 17
    Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Ann Rheum Dis2010;69:5228.
  • 18
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al.Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.J Rheumatol2007;34:70611.
  • 19
    Wolfe F, Michaud K, Anderson J, Urbansky K.Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.Arthritis Rheum2004;50:3729.
  • 20
    Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al.Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan.Ann Rheum Dis2006;65:16613.
  • 21
    Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al.Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry.Arthritis Rheum2009;60:188494.
  • 22
    World Health Organization (WHO). Global health observatory data repository: world health statistics, tuberculosis: Canada.2010. URL:
  • 23
    Lobue P, Menzies D.Treatment of latent tuberculosis infection: an update.Respirology2010;15:60322.
  • 24
    Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al.An official ATS statement: hepatotoxicity of antituberculosis therapy.Am J Respir Crit Care Med2006;174:93552.
  • 25
    Fountain FF, Tolley E, Chrisman CR, Self TH.Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.Chest2005;128:11623.
  • 26
    LoBue PA, Moser KS.Use of isoniazid for latent tuberculosis infection in a public health clinic.Am J Respir Crit Care Med2003;168:4437.
  • 27
    Mor A, Bingham CO III, Kishimoto M, Izmirly PM, Greenberg JD, Reddy S, et al.Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic.Ann Rheum Dis2008;67:4625.
  • 28
    Smieja MJ, Marchetti CA, Cook DJ, Smaill FM.Isoniazid for preventing tuberculosis in non-HIV infected persons.Cochrane Database Syst Rev2000;2:CD001363.
  • 29
    International Union Against Tuberculosis Committee on Prophylaxis.Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.Bull World Health Organ1982;60:55564.
  • 30
    Meune C, Touze E, Trinquart L, Allanore Y.Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies.Rheumatology (Oxford)2009;48:130913.
  • 31
    Sokka T, Abelson B, Pincus T.Mortality in rheumatoid arthritis: 2008 update.Clin Exp Rheumatol2008;26 Suppl 51:S3561.
  • 32
    Statistics Canada. Complete life table, Canada: 2000 to 2002.2006. URL:
  • 33
    Kaplan RM, Groessl EJ, Sengupta N, Sieber WJ, Ganiats TG.Comparison of measured utility scores and imputed scores from the SF-36 in patients with rheumatoid arthritis.Med Care2005;43:7987.
  • 34
    Rashidi AA, Anis AH, Marra CA.Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients.Health Qual Life Outcomes2006;4:25.
  • 35
    Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, Fitzgerald JM.Health state utilities in latent and active tuberculosis.Value Health2008;11:115461.
  • 36
    Briggs AH, Goeree R, Blackhouse G, O'Brien BJ.Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease.Med Decis Making2002;22:290308.
  • 37
    National Institute for Health and Care Excellence (NICE). NICE clinical guideline 117: tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control.2011. URL:
  • 38
    Ziakas PD, Mylonakis E.Four months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.Clin Infect Dis2009;49:18839.
  • 39
    Smith BM, Menzies D.Treatment of latent TB: first do no harm.Expert Rev Anti Infect Ther2011;9:4913.
  • 40
    Smith BM, Schwartzman K, Bartlett G, Menzies D.Adverse events associated with treatment of latent tuberculosis in the general population.CMAJ2011;183:E1739.
  • 41
    Salpeter SR, Sanders GD, Salpeter EE, Owens DK.Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.Ann Intern Med1997;127:105161.
  • 42
    Colice GL.Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors.Arch Intern Med1990;150:251722.
  • 43
    Rose DN, Schechter CB, Silver AL.The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors.JAMA1986;256:270913.
  • 44
    Holland DP, Sanders GD, Hamilton CD, Stout JE.Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.Am J Respir Crit Care Med2009;179:105560.
  • 45
    De Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH.Cost-effectiveness of interferon γ release assays vs. tuberculin skin tests in health care workers.Arch Intern Med2009;169:17987.
  • 46
    Jick SS, Lieberman ES, Rahman MU, Choi HK.Glucocorticoid use, other associated factors, and the risk of tuberculosis.Arthritis Rheum2006;55:1926.
  • 47
    Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al.A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries.Semin Arthritis Rheum2010;40:214.
  • 48
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, for the Biobadaser Group.Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.Arthritis Rheum2003;48:21227.